Pirfenidone in idiopathic pulmonary fibrosis

Lancet

Volumn 354, Issue 9175, 1999, Pages 268-269

  Nicod, L P ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PIRFENIDONE; PYRIDINE DERIVATIVE;

IDIOPATHIC DISEASE; LUNG FIBROSIS; NOTE; PRIORITY JOURNAL;

EID: 0033600396     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)00178-6     Document Type: Note

References (13)

1. Nicod L.P. Recognition and treatment of idiopathic pulmonary fibrosis. Drugs. 55:1998;555-556.
2. Stewart J.P., Egan J.I., Ross A.J.et al. The detection of Epstein-Barr virus DNA in lung tissue from patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 159:1999;1336-1341.
3. Lemjabbar H., Gosset P.h., Lechapt-Zaleman E.et al. Overexpression of alveolar macrophage gelatinase B (MMP-9) in patients with idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol. 20:1999;903-913.
4. McAnulty R.J., Laurent G.J. Pathogenesis of lung fibrosis and potential new therapeutic strategies. Expt Nephrol. 3:1995;96-107.
5. Raghu G., Depaso W.J., Cain K.et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis : a prospective double-blind, randomized placebo-controlled clinical trial. Am Rev Respi Dis. 144:1991;191-196.
6. Douglas W.W., Ryu J.H., Swensen J.et al. Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 158:1998;220-225.
7. Meier-Sydow J., Rust M., Kronenberger H. Long-term follow-up of lung function parameters in patients with idiopathic pulmonary fibrosis treated with prednisone and azathioprine or D-penicillamine. Prax Pneumol. 33:1979;680-688.
8. Kaneko M., Inoue H., Nakazawa R.et al. Pirfenidone induces intercellular adhesion molecule-1 (ICAM-1) down-regulation on cultured human synovial fibroblasts. Clin Exp Immunol. 113:1998;72-76.
9. Lee B.S., Margolin S.B., Nowak R.A. Pirfenidone: a novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production. J Clin Endocrinol Metab. 83:1998;219-223.
10. Cain W.C., Sturat R.W., Lefkowitz D.L., Starnes J.D., Margolin S., Lefkowitz S.S. Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone. Int J Immunopharmacol. 20:1998;685-695.
11. Iyer S.N., Margolin S.B., Hyde D.M., Giri S.N. Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin-hamster model. Exp Lung Res. 24:1998;119-132.
12. Raghu G., Johnson W., Lockhart D., Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone. Am J Respir Crit Care Med. 159:1999;1061-1069.
13. Katzenstein A.L., Myers J.L. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med. 157:1998;1301-1315.